Synaffix Enters into a Commercial License Agreement with ADC Therapeutics
Synaffix BV announced today it has entered into a Commercial License Agreement with ADC Therapeutics for its proprietary GlycoConnect™ and HydraSpace™ site-specific antibody-drug conjugate technologies.
Read more
BioConnection wins FD Gazellen Award
BioConnection proudly announced that it has won the FD Gazellen status.
Read more
Catalyze opent kantoor op Pivot Park
Catalyze is een consultancy bedrijf gespecialiseerd in het ophalen van financiering voor de biotechnologie en life sciences industrie.
Read more
LOI binding or not?
Since May of this year Bogaerts & Groenen advocaten is present at Pivot Park.
Read more
NTRC publishes Comparative Oncolines™ profiling of 122 anti-cancer agents in Molecular Cancer Therapeutics
NTRC scientists describe the comparative analysis of the anti-proliferative activity of 122 publicly known anti-cancer agents in the Oncolines™ cell panel.
Read more
New generation of multi-disciplinary nanotechnology experts
NANOMED is a EU funded collaboration between universities and companies active in the field of nanomedicines.
Read more
Innatoss Laboratories ontvangt € 2 miljoen voor Europese Lyme-innovatie
De Europese Unie verleent bijna € 2.000.000 subsidie aan een internationaal consortium dat werkt aan een nieuwe test voor de ziekte van Lyme.
Read more
Synaffix Achieves Significantly Improved Therapeutic Index
Synaffix Achieves Significantly Improved Therapeutic Index Compared to Both FDA-Approved ADCs and expands its Scientific Advisory Board.
Read more
Iers bedrijf ESP opent Nederlands kantoor op Pivot Park
Enterprise System Partners (ESP) heeft recent haar kantoor op het Pivot Park in Oss betrokken.
Read more